ENDRA Life Sciences Inc (NDRA) — Cash Flow-to-Debt Ratio
ENDRA Life Sciences Inc (NDRA) has a Cash Flow-to-Debt Ratio of -1.01x as of December 2025, meaning its operating cash flow of $-1.61 Million could theoretically repay -1% of its total liabilities ($1.59 Million) in one year. See ENDRA Life Sciences Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ENDRA Life Sciences Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for ENDRA Life Sciences Inc across 12 annual periods. Also explore ENDRA Life Sciences Inc annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for ENDRA Life Sciences Inc (2014–2025)
Year-by-year debt coverage analysis for ENDRA Life Sciences Inc. For market capitalisation and broader financial context, see ENDRA Life Sciences Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.25x | $-5.18 Million | $1.59 Million | ▲ +16.9% |
| 2024 | -3.91x | $-7.40 Million | $1.89 Million | ▲ +55.1% |
| 2023 | -8.72x | $-9.55 Million | $1.10 Million | ▼ -41.3% |
| 2022 | -6.17x | $-12.77 Million | $2.07 Million | ▼ -16.0% |
| 2021 | -5.32x | $-11.12 Million | $2.09 Million | ▲ +21.2% |
| 2020 | -6.75x | $-10.77 Million | $1.60 Million | ▼ -89.8% |
| 2019 | -3.56x | $-8.59 Million | $2.42 Million | ▲ +55.0% |
| 2018 | -7.90x | $-7.70 Million | $974.58K | ▼ -103.1% |
| 2017 | -3.89x | $-3.30 Million | $848.21K | ▼ -309.5% |
| 2016 | -0.95x | $-1.32 Million | $1.38 Million | ▲ +73.3% |
| 2015 | -3.56x | $-842.73K | $236.42K | ▲ +75.1% |
| 2014 | -14.32x | $-1.40 Million | $97.60K | — |